- NMS-E973
-
- $58.00 / 5mg
-
2025-07-16
- CAS:1253584-84-7
- Min. Order:
- Purity: 99.82%
- Supply Ability: 10g
|
| | 5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide Basic information |
| Product Name: | 5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide | | Synonyms: | NMS-E973;5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide;3-Isoxazolecarboxamide, 5-[2,4-dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-;5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide USP/EP/BP;NMS-E973,Leukemia,NMS E973,inhibit,HSP,Heat shock proteins,Adenocarcinoma,Hsp90α,ovary,colon,breast,cancer,Carcinoma,Neuroblastoma,NMSE973,NMS-E-973,Melanoma,Inhibitor;5-(2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl)-N-(1-methylpiperidin-4-yl)isoxazole-3-carboxamide;NMS-E973, 10 mM in DMSO | | CAS: | 1253584-84-7 | | MF: | C22H22N4O7 | | MW: | 454.43 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1253584-84-7.mol | ![5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide Structure](CAS/20180629/GIF/1253584-84-7.gif) |
| | 5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide Chemical Properties |
| Boiling point | 686.9±55.0 °C(Predicted) | | density | 1.50±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder | | pka | 5.69±0.20(Predicted) | | color | Off-white to yellow |
| | 5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide Usage And Synthesis |
| Uses | NMS-E973 is a potent and selective inhibitor of HSP90. NMS-E973 binds to the ATP binding site of Hsp90α with a DC50 of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy[1]. | | Biological Activity | nms-e973 is a potent and selective inhibitor of heat shock protein 90 (hsp90) with dc50 value of < 10nm [1].since hsp90 plays an important role in the conformational maturation, stability and function of some oncogenic proteins, the inhibitors of hsp90 are developed as therapeutic for cancers. nms-e973 is a selective inhibitor of hsp90. it binds to hsp90α within the atp binding site with dc50 value of < 10nm. besides that, nms-e973 shows no effect on a panel of 52 various protein kinases such as abl, ack1, akt1 and alk. the ic50 value of it for hsc70 is > 10μm. nms-e973 exerts antiproliferation effects on a2780 tumor cell line and bt-474 breast cancer cell line with ic50 values of 69nm and 110nm, respectively. when treated with mice bearing a2780 xenografts, the intravenous administration of nms-e973 significantly inhibits tumor growth with tgi value of 53% at dose of 30mg/kg. moreover, nms-e973 also displays antitumor activity in tumors resistant to kinase inhibitors such as vemurafenib [1, 2]. | | in vivo | NMS-E973 (60 mg/kg; i.v.) inhibits the growth of A375 tumors subcutaneously or intracranially implanted in mice[1].
NMS-E973 exhibits moderate elimination half-lives (5.55±1.07 h) due to high plasma clearance (39.9±1.70 mL/min/kg) combined with large volumes of distribution (5.83±3.18 L/kg) following intravenous administration (10 mg/kg) in mice[1]. | Animal Model: | Balb/c male nude mice (aged 6 to 8 weeks) xenografted with the A375 tumors[1] | | Dosage: | 60 mg/kg | | Administration: | Administered twice daily i.v. according to 2 schedules: (i) every other day for 12 days and (ii) 3 days on/1 day off/3 days on (3-1-3, one cycle). | | Result: | Both schedules resulted in tumor shrinkage and TGI of 74% and 89%, respectively. |
| | target | Hsp90 | | IC 50 | HSP90α: 10 nM (DC50) | | references | [1] brasca m g, mantegani s, amboldi n, et al. discovery of nms-e973 as novel, selective and potent inhibitor of heat shock protein 90 (hsp90). bioorganic & medicinal chemistry, 2013, 21(22): 7047-7063.
[2] fogliatto g, gianellini l, brasca m g, et al. nms-e973, a novel synthetic inhibitor of hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases. clinical cancer research, 2013, 19(13): 3520-3532. |
| | 5-[2,4-Dihydroxy-6-(4-nitrophenoxy)phenyl]-N-(1-methyl-4-piperidinyl)-3-isoxazolecarboxamide Preparation Products And Raw materials |
|